Participate in a Unique Global Discussion (from Europe, USA,
Canada, Middle East to Asia) about the Deployment of Precision Oncology
June 23-24, 2019, Paris, France
VILLEJUIF, France–(BUSINESS WIRE)–The
11th WIN Symposium in Precision Oncology will be held in Paris,
France on June 23-24, 2019.
ASCO® endorsed for the past 11 years, the WIN symposium will deliver an
exciting line-up of speakers in Paris (France) on June 23-24, 2019 to
discuss Innovation and Global Deployment of Precision Oncology.
The
current status of Precision Oncology across the globe will be examined
with the exceptional participation of the chairmen of the event, Richard
L. Schilsky, Chairman WIN Consortium(*), Senior
Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero,
Vice Chairman WIN Consortium, President of ESMO and Director of Vall
d’Hebron Institute of Oncology, Spain.
Global experience will be shared:
-
Optimizing Patient Enrollment and Efficacy of Precision Oncology
Clinical Trials at UT MD Anderson Cancer Center, USA -
Decision Support for Precision Oncology: Evolving from Monotherapy to
Genomically Informed Combinations, UT MD Anderson Cancer Center, USA -
The Value of Personalized Medicines for Healthcare Systems in Europe –
by the European Biopharmaceutical Enterprises (EBE) and the European
Federation of Pharmaceutical Industries and Associations (EFPIA) -
Rapidly changing landscape of Precision Medicine in Japan, Tokyo
Medical and Dental University -
National Cancer Grid of India – Earthshots over Moonshots, TATA
Memorial Hospital -
Development and Application of Precision Oncology in China, Fudan
University Shanghai Cancer Center
World leading precision oncologists will deliver breakthrough science,
including:
-
Prof. Jennifer A. Doudna, PhD, University of California,
Berkeley, USA “Rewriting the Code of Life: CRISPR-Cas
Genome Editing”. -
Dr. Jennifer A. Ligibel, MD, Harvard Medical School and Dana
Farber Cancer Institute, USA “Lifestyle-based Prevention
Strategies”. -
Dr. Razelle Kurzrock, MD, University of California, San Diego, USA, “Innovation
in Clinical Trials: WINTHER trial”, first study pioneered by the WIN
Consortium(*), that showed that assessing RNA is an
important adjunct to DNA profiling for determining treatments and
rings in a new era for personalized medicine in oncology. WINTHER
results were recently published in Nature
Medicine (**) -
Prof. Christophe Le Tourneau, MD., PhD, Institut Curie, France, “Innovative
Ways of Assessing Durable Response under Immunotherapy” -
Dr. Jean François Martini, PhD., MSc, Pfizer Inc., “Addressing
Mechanisms of Resistance Following Anti-Cancer Therapy: a Pharma
Perspective” -
Prof. Angel Porgador, PhD, Ben Gurion University of Negev, Israel, “Efficient
In Vitro Screening for Drug Combinations: The TEVA Model”
Do not miss the two microsatellites hosted at the WIN Symposium:
-
Real-World Evidence and its Relevance for Clinical Practice and
Stakeholder Decision Making – F. Hoffmann-La Roche Ltd -
Artificial Intelligence to Support Patient Profiling in Precision
Oncology – Definiens AG
The WIN symposium provides outstanding networking opportunities for all
professionals in cancer care.
(*) WIN
Consortium is a non-profit organization based in Paris, France. We
are a worldwide network assembling cancer stakeholders from four
continents to develop cutting edge concepts and clinical trials that
improve survival for cancer patients. WIN members include 28 outstanding
cancer centers plus 11 additional leading pharmaceutical, technology
companies and patient advocacy organizations representing stakeholders
in precision cancer medicine, www.winconsortium.org
(**) Genomic and transcriptomic profiling expands
precision cancer medicine: the WINTHER trial https://doi.org/10.1038/s41591-019-0424-4
For more information: www.winsymposium.org
ASCO® is a registered trademark of the American Society of Clinical
Oncology®. Used with permission. This is not an ASCO sponsored event.
Contacts
WIN Consortium
Vladimir Lazar
Chief Scientific and Operating
Officer
vladimir.lazar@winconsortium.org
Telephone:
+ 33 66 109 15 22